文献速递乳腺癌

循环肿瘤DNA分析指导晚期乳腺癌治疗(plasmaMATCH):多中心、多队列、2a期平台试验

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
PubMed 文献 · Lancet Oncol · 2020-09-10

plasmaMATCH是一项多中心、多队列、2a期平台试验,评估ctDNA检测在晚期乳腺癌中的准确性及指导突变靶向治疗的能力。研究纳入1051例患者,ctDNA结果可评估者1034例,ctDNA数字PCR与靶向测序一致性达96-99%,对组织测序突变灵敏度总体93%(95%CI 83-98),同期活检达98%(87-100)。队列B(HER2突变)和C(AKT1突变/ER阳性)达到预设缓解数,客观缓解率分别为25%(5/20)和22%(4/18);队列A(ESR1突变)和D(AKT1突变/ER阴性或PTEN突变)未达目标,缓解率分别为8%(6/74)和11%(2/19)。

要点

  • ctDNA检测与组织测序一致性高,灵敏度总体93%(95%CI 83-98),同期活检达98%。
  • 队列B(HER2突变)5/20缓解(25%),队列C(AKT1突变/ER阳性)4/18缓解(22%),达到预设目标。
  • 队列A(ESR1突变)6/74缓解(8%),队列D(AKT1突变/ER阴性或PTEN突变)2/19缓解(11%),未达目标。

核心结论

  • ctDNA检测可提供准确、快速的基因分型,能够筛选适合突变靶向治疗的患者,具有足够临床效度用于常规实践。
  • 针对罕见HER2和AKT1突变的靶向治疗显示出临床相关活性,确认这些突变可作为乳腺癌治疗靶点。

研究设计与样本

  • 开放标签、多队列、2a期平台试验,在英国18家医院开展。
  • 入组年龄≥18岁女性,组织学确诊晚期乳腺癌,ECOG体能状态0-2,既往至少一线晚期治疗或新辅助/辅助化疗后12个月内复发。
  • 1051例患者注册,1034例有ctDNA结果;按ctDNA突变分入四个平行治疗队列:A(ESR1突变,氟维司群500mg肌注延长剂量)、B(HER2突变,奈拉替尼240mg口服,ER阳性者联合标准剂量氟维司群肌注)、C(AKT1突变且ER阳性,capivasertib 400mg口服联合标准剂量氟维司群肌注)、D(AKT1突变且ER阴性或PTEN突变,capivasertib 480mg口服)。

主要发现

  • 数字PCR ctDNA对组织测序突变的灵敏度总体93%(95%CI 83-98),同期活检98%(87-100)。
  • 队列B 5/20缓解(25% [95%CI 9-49]),队列C 4/18缓解(22% [6-48]),达到或超过目标缓解数。
  • 队列A 6/74缓解(8% [95%CI 3-17]),队列D 2/19缓解(11% [1-33]),未达目标缓解数。

关键数值与推荐

  • 队列A需78例可评估患者中≥13例缓解以推断活性;队列B、C、D需16例中≥3例缓解。
  • 最常见3-4级不良事件:队列A为γ-谷氨酰转移酶升高(13/80,16%);队列B为腹泻(4/20,25%);队列C为疲乏(4/18,22%);队列D为皮疹(5/19,26%)。
  • 11例患者发生17起严重不良反应,1例治疗相关死亡(队列C,4级呼吸困难)。

临床怎么用

  • ctDNA检测可用于晚期乳腺癌的快速基因分型,指导突变靶向治疗选择。
  • HER2和AKT1突变可作为乳腺癌靶向治疗的可行动靶点。

局限性

  • 研究为2a期平台试验,各队列样本量较小。
  • 长期随访仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy. METHODS: We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncology Group performance status 0-2. Patients had completed at least one previous line of treatment for advanced breast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA: cohort A comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B comprised patients with HER2 mutations (treated with oral neratinib 240 mg, and if oestrogen receptor-positive with intramuscular standard-dose fulvestrant); cohort C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant); and cohort D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation (treated with oral capivasertib 480 mg). Each cohort had a primary endpoint of confirmed objective response rate. For cohort A, 13 or more responses among 78 evaluable patients were required to infer activity and three or more among 16 were required for cohorts B, C, and D. Recruitment to all cohorts is complete and long-term follow-up is ongoing. This trial is registered with ClinicalTrials.gov, NCT03182634; the European Clinical Trials database, EudraCT2015-003735-36; and the ISRCTN registry, ISRCTN16945804. FINDINGS: Between Dec 21, 2016, and April 26, 2019, 1051 patients registered for the study, with ctDNA results available for 1034 patients. Agreement between ctDNA digital PCR and targeted sequencing was 96-99% (n=800, kappa 0·89-0·93). Sensitivity of digital PCR ctDNA testing for mutations identified in tissue sequencing was 93% (95% CI 83-98) overall and 98% (87-100) with contemporaneous biopsies. In all cohorts, combined median follow-up was 14·4 months (IQR 7·0-23·7). Cohorts B and C met or exceeded the target number of responses, with five (25% [95% CI 9-49]) of 20 patients in cohort B and four (22% [6-48]) of 18 patients in cohort C having a response. Cohorts A and D did not reach the target number of responses, with six (8% [95% CI 3-17]) of 74 in cohort A and two (11% [1-33]) of 19 patients in cohort D having a response. The most common grade 3-4 adverse events were raised gamma-glutamyltransferase (13 [16%] of 80 patients; cohort A); diarrhoea (four [25%] of 20; cohort B); fatigue (four [22%] of 18; cohort C); and rash (five [26%] of 19; cohort D). 17 serious adverse reactions occurred in 11 patients, and there was one treatment-related death caused by grade 4 dyspnoea (in cohort C). INTERPRETATION: ctDNA testing offers accurate, rapid genotyping that enables the selection of mutation-directed therapies for patients with breast cancer, with sufficient clinical validity for adoption into routine clinical practice. Our results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, confirming these mutations could be targetable for breast cancer treatment. FUNDING: Cancer Research UK, AstraZeneca, and Puma Biotechnology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Turner NC, Kingston B, Kilburn LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020. PMID: 32919527. doi:10.1016/S1470-2045(20)30444-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。